Skip to main content

Table 1 Study and Clinicopathological characteristics of 13 included studies

From: Prostate-specific membrane antigen positron emission tomography (PSMA-PET) for local staging of prostate cancer: a systematic review and meta-analysis

  Study characteristics Clinicopathological characteristics
Origin Design Endpoint No. of patients Age (year) PSA (ng/mL) Gleason score Risk group
Author, publication year Institution Country Enrollment period Prospective Multicenter
Agrawal A, 2017 TATA Memorial Hospital India NR No No SVI 35 NR (47-73) NR (NR) NR (NR) NR
Berger I, 2018 Nepean Hospital Australia Feb. 2015-Jan. 2017 No No SVI 50 64.9a (± 5.6) 10.6a (± 8.1) 7 [4 + 3] (6-9) bLow, intermediate, high
Dekalo S, 2019 Tel-Aviv Sourasky Medical Center Israel NR No No SVI 59 65.35* (± 6.99) 12.97a (11.88) 7 [4 + 3] (7-9) Intermediate, high
Fendler WP, 2016 Ludwig-Maximilians-University of Munich Germany Jan. 2014-April 2015 No No SVI, EPE 21 70.1a (± 5.9) 58.7a (± 85.2) 7 [4 + 3] (6-9) High
Gao J, 2019 Drum Tower Hospital China Nov. 2017-Dec. 2018 No No SVI, EPE 49 69 (55-82) 15.94 (4.04-72.05) 7 [4 + 3] (7-8) Intermediate, high
Grubmuller B, 2018 Medical University of Vienna Austria April 2014-July 2017 Yes No SVI, EPE 80 64 (59-71) 7.63 (5.5-13.4) 7 (6- > 8) Intermediate, high
Gupta M, 2018 Rajiv Gandhi Cancer Institute and Research Centre India July 2014-March 2017 No No SVI, EPE 23 66 (38-88) NR (≤ 10- > 20) NR (6-10) Intermediate, high
Muehlematter UJ, 2019 University Hospital Zurich Switzerland April 2016-July 2018 No No SVI, EPE 40 63a (± 6) 8.12 (IQR 7.56) 8 (7-9) Intermediate, high
Thalgot M, 2018 Klinikum Rechts der Isar Germany Dec. 2012-Nov. 2015 No No SVI, EPE 73 68 (63-73) 14.0 (6-35) 8 (6-10) High
van Leeuwen PJ, 2019 St Vincent’s Hospital, Netherlands Cancer Institute Australia, Netherlands Feb. 2015-Oct. 2017 No Yes SVI 140 NR 9.4 (NR) 8 (7-9) Intermediate, high
von Klot CAJ, 2017 Hannover Medical School Germany NR No No SVI, EPE 21 68 (56-77) 11.9a (NR) 7 [3 + 4] (6-10) Intermediate, high
Yilmaz B, 2019 Istanbul Research and Training Hospital Turkey May 2016-April 2018 No No SVI, EPE 24 62.8a (± 6.4) 12.0a (± 7.4) 7 [4 + 3] (6-9) bLow, intermediate, high
  1. CT Computed tomography, EPE Extraprostatic extension, MRI Magnetic resonance imaging, NR Not reported, PET Positron emission tomography, PSA Prostate-specific antigen, PSMA Prostate-specific membrane antigen, SVI Seminal vesical invasion
  2. aData presented in mean ± standard deviation; others are presented in median and ranges
  3. bPredominantly intermediate to high-risk patients as there were only 1 (at most) and 3 patients within the low-risk category in the studies by Berger et al. (2018) and Yilmaz et al. (2019), respectively